Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Publikation

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Wissenschaftlicher Artikel/Review - 20.01.2023

Taylor Peter C, Chen Yun-Fei, Pope Janet E, Weinblatt Michael, Mysler Eduardo F, Rubbert-Roth Andrea, Jia Bochao, Sun Luna, Liu Yushi, Holzkämper Thorsten, Tanaka Yoshiya

Zitation

Taylor P, Chen Y, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther 2023; 10:463-476.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Rheumatol Ther 2023; 10

Veröffentlichungsdatum

20.01.2023

ISSN (Druck)

2198-6576

Seiten

463-476

Kurzbeschreibung/Zielsetzung

We sought to identify and compare treatment response groups based on individual patient responses (rather than group mean response) over time on the Clinical Disease Activity Index (CDAI) for rheumatoid arthritis (RA), in patients treated with baricitinib 4-mg in 4 phase 3 studies.